Brain connectivity disruption is a hallmark of neurodegenerative disorders, including Alzheimer's disease (AD), yet how network breakdown gives rise to cognitive deficits remains unclear. Here, we review the evidence bearing on three interconnected processes that have been proposed to link molecular pathology to cognit...
L. Pini, Catalina Campuzano, Lu Zhang et al.· Neuroscience and Biobehavior...· 0 citations
Abstract Recent studies show that serum glial fibrillary acidic protein (GFAP) is highest in healthy infancy and early childhood and then declines steadily with age, while plasma tau protein phosphorylated at position 217 is strikingly elevated in healthy newborns and can exceed values observed in Alzheimer’s disease (...
L. Pini, M. Margoni, Massimo Filippi et al.· Brain Communications· 0 citations
Interventions for Alzheimer's disease (AD) have repeatedly been advanced from epidemiological associations, biological hypotheses and preclinical findings, yet many have failed in randomized trials and some have produced signals of clinical worsening. We examine illustrative successful and unsuccessful programs across...
B. Imbimbo, Nunzio Pomara, L. Pini et al.· Biomedicine & pharmacotherap...· 0 citations
A dual‐domain framework is proposed in which tau‐targeted therapies are evaluated using complementary measures of aggregated tau burden and biologically defined soluble tau states, and treatment‐induced increases should be considered favorable only when they accompany aggregate reduction and evidence of a less pathogen...
C. Teunissen, L. Pini, B. Imbimbo· Alzheimer's & Dementia· 0 citations
It is concluded that [18F]-Florzolotau PET provides a robust in vivo measure of AD tau burden, motivating further evaluation for diagnostic and prognostic applications.
Simone Lista, P. Minoretti, Enzo Emanuele et al.· Journal of Alzheimer's Disea...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
